Mitochondrial dysfunction is a key process associated with neurodegeneration and therefore, a promising therapeutic target for new causal drugs against AD is to eliminate both the formation and mitochondrial toxicity of Aβ and tau oligomers [56,86]. Here, MAPT is linked to Alzheimer disease.